SEC Filing Summary: Check-Cap Ltd. (Form 20-F)
Business Context and Reporting Period
Company: Check-Cap Ltd. (Note: Input metadata referenced "Mbody AI Ltd.", but the filing text identifies the registrant as Check-Cap Ltd.)
Reporting Period: Fiscal year ended December 31, 2015
Business Overview: Check-Cap is a clinical-stage medical diagnostics company developing an ingestible capsule system using ultra low-dose X-rays to detect colonic polyps and colorectal cancer (CRC). The system is designed to operate without bowel preparation or fasting. The company has no commercial revenue to date and is focused on completing clinical trials and obtaining regulatory approvals (CE Mark in Europe, FDA clearance in the U.S.).
Accounting Basis: The company transitioned from IFRS to U.S. GAAP beginning in the fourth quarter of 2015. Comparative amounts have been recast.
Key Financial Metrics
| Metric (US$ in thousands) | 2015 | 2014 | 2013 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Expenses | $12,463 | $4,535 | $3,972 |
| Research & Development (net) | $5,837 | $2,832 | $2,893 |
| General & Administrative | $6,626 | $1,703 | $1,090 |
| Operating Loss | $(12,463) | $(4,535) | $(3,972) |
| Net Loss | $(12,290) | $(610) | $(3,368) |
| Cash and Cash Equivalents (Year End) | $9,392 | $1,075 | $4,975 |
| Working Capital | $12,856 | $(1,622) | $4,134 |
| Total Shareholders' Equity | $12,648 | $(826) | $(528) |
Note: The company incurred a net loss of $12.3 million in 2015 compared to $0.6 million in 2014. Cash position improved significantly due to an IPO and concurrent private placement consummated in February 2015, raising approximately $22.5 million in gross proceeds (net proceeds approx. $22.8 million including prior year credit line drawdowns and grants).
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased by 178% year-over-year. R&D expenses doubled (107% increase) due to clinical trial costs and hiring 28 new R&D staff. G&A expenses increased 288% primarily due to share-based compensation ($2.7 million increase) and costs associated with the IPO and public company compliance.
- Financing Activity: The company completed an IPO and private placement in early 2015, transforming its liquidity position from a negative working capital of $(1.6) million in 2014 to positive working capital of $12.9 million in 2015.
- Accounting Transition: Financial statements were recast to U.S. GAAP from IFRS, affecting comparability of certain line items.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Revenue: No revenue is anticipated for the foreseeable future.
- Regulatory Timeline: Plans to submit for CE Marking in the EU in H2 2016, with a potential commercial launch in Europe in 2017. A U.S. pivotal study is planned for 2017, with a direct de novo reclassification petition to the FDA anticipated in 2018.
- Liquidity: Management believes current cash resources and IPO proceeds will fund operations through March 31, 2017. Additional financing will be required thereafter.
Key Risks and Contingencies:
- Regulatory Approval: Failure to obtain FDA clearance (via de novo or PMA) or CE Marking would prevent commercialization. The FDA may require a more costly PMA pathway.
- Clinical Failure: Clinical trials may fail to demonstrate safety or efficacy, or reveal adverse side effects.
- Capital Requirements: The company has a history of losses and an accumulated deficit of $34.1 million. Continued losses are expected until commercialization.
- Manufacturing and Supply Chain: Reliance on single-source suppliers for critical components (X-ray source, motor, detectors) and limited commercial manufacturing experience.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability.
- Intellectual Property: Risks of infringement claims or inability to protect patents in key markets.
Investor Verification Checklist
- Cash Runway: Verify if the $9.4 million cash balance (as of Dec 31, 2015) is sufficient to meet the projected burn rate through the planned 2017 U.S. pivotal study, given the high cost of clinical trials.
- Regulatory Pathway: Confirm the FDA's stance on the "direct de novo" reclassification strategy versus the potential requirement for a Premarket Approval (PMA), which is significantly more expensive and time-consuming.
- Share-Based Compensation: Review the impact of the $3.7 million share-based compensation expense in 2015 on future dilution and cash flow.
- Government Grants: Assess the contingent obligations to the Israeli Office of the Chief Scientist (OCS) and BIRD Foundation, which require royalty payments on future revenues and restrict manufacturing locations.
- Single-Source Suppliers: Evaluate the risk mitigation strategies for the single-source suppliers of the X-ray source and ASIC components.